citalopram has been researched along with Local Neoplasm Recurrence in 4 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen." | 7.76 | Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2010) |
| "Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours." | 7.74 | Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2008) |
| " Of the 125 evaluable patients with stages II through IV HNC but without baseline depression, 60 were randomized to prophylactic antidepressant escitalopram oxalate and 65 to placebo at the time of the initial diagnosis." | 5.27 | Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( Burke, WJ; Lydiatt, WM; Panwar, A; Rieke, K; Sayles, H, 2018) |
| "Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen." | 3.76 | Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2010) |
| "Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours." | 3.74 | Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panwar, A | 1 |
| Rieke, K | 1 |
| Burke, WJ | 2 |
| Sayles, H | 1 |
| Lydiatt, WM | 2 |
| Lash, TL | 2 |
| Pedersen, L | 2 |
| Cronin-Fenton, D | 2 |
| Ahern, TP | 2 |
| Rosenberg, CL | 2 |
| Lunetta, KL | 2 |
| Silliman, RA | 2 |
| Hamilton-Dutoit, S | 2 |
| Garne, JP | 2 |
| Ewertz, M | 2 |
| Sørensen, HT | 2 |
| Lazure, KE | 1 |
| Denman, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer[NCT05724849] | Phase 2 | 64 participants (Anticipated) | Interventional | 2023-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for citalopram and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Female; Head | 2018 |
Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Carcinoma, Squamous Cell; | 2009 |
2 other studies available for citalopram and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Citalopram; Dr | 2008 |
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neopl | 2010 |